BackPharmaxis Overview

Pharmaxis Profit Margin

Valuation check: PMXSF's profit margin is -278.5%, below the sector sector average of 13.4%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

N/A

As of Jun 2026

Annual Profit Margin (TTM)

-278.50%
↓ 209.89% YoY

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Pharmaxis (PMXSF) FAQ

The latest profit margin for PMXSF is -278.5% as of June 2026. That compares with -89.87% in the prior-year period — down 209.9% year over year. That is below the sector sector average of 13.4%. Investors often review this figure alongside Pharmaxis's historical trend and sector peers before judging valuation or financial health.

Over the past year, PMXSF's profit margin moved from -89.87% to -278.5% — a 209.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pharmaxis's valuation or profitability profile.

Against its sector companies, PMXSF currently prints -278.5% for profit margin, while the sector average sits near 13.4%. That is roughly 2177.8% below the sector mean. Large gaps often invite a closer look at Pharmaxis's growth, margins, and balance sheet.

Profit Margin shows how effectively Pharmaxis converts resources into returns. At -278.5%, PMXSF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -89.87% in the prior-year period — down 209.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PMXSF's profit margin (-278.5%), review year-over-year change from -89.87%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.